Grünenthal Group
Andrew Lockhart has extensive experience in the pharmaceutical industry, holding roles at companies such as Grünenthal Group, Sosei Heptares, GlaxoSmithKline, and Novartis. Andrew has served in leadership positions such as Senior Vice President and Programme Director, specializing in areas such as translational medicine and discovery medicine unit. Prior to their industry roles, they worked as a Postdoctoral Researcher at the Medical Research Council and the Marie Curie Research Institute, focusing on structural studies and protein chemistry.
Andrew Lockhart attended the University of Surrey from 1984 to 1988, earning a BSc in Biochemistry. Andrew then pursued a PhD in Protein Chemistry at Birkbeck, University of London from 1998 to 2001.
This person is not in the org chart
Grünenthal Group
5 followers
Grünenthal is a global leader in pain management and related diseases. As a science-based privately-owned pharmaceutical company, they have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide.